MicroRNA-18a inhibits hypoxia-inducible factor 1¿ activity and lung metastasis in basal breast cancers
Conclusions:
This study reveals a novel role for miR-18a to target HIF1A and repress metastasis of basal-like breast tumors. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 28, 2014 Category: Cancer & Oncology Authors: Raisa KrutilinaWenlin SunAarti SethuramanMartin BrownTiffany SeagrovesLawrence PfefferTatyana IgnatovaMeiyun Fan Source Type: research
MicroRNA-18a inhibits hypoxia-inducible factor 1-alpha activity and lung metastasis in basal breast cancers
Conclusions:
This study reveals a novel role for miR-18a to target HIF1A and repress metastasis of basal-like breast tumors. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 28, 2014 Category: Cancer & Oncology Authors: Raisa KrutilinaWenlin SunAarti SethuramanMartin BrownTiffany SeagrovesLawrence PfefferTatyana IgnatovaMeiyun Fan Source Type: research
A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype
Conclusions:
Our findings suggest that an EMT-related gene signature in the tumor epithelium is related to both stromal activation and escape from disease dormancy in breast cancer. The presence of a late recurrence gene signature in the primary tumor also suggests that intrinsic features of this tumor regulate the transition of disseminated tumor cells into a dormant phenotype with the ability to outgrowth as recurrent disease. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 25, 2014 Category: Cancer & Oncology Authors: Qing ChengJeffrey ChangWilliam GwinJun ZhuStefan AmbsJoseph GeradtsH Lyerly Source Type: research
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression
Conclusion:
Integration of metabolomics, molecular and pathological approaches reveals the interplay between cancer and stroma via COX-2 and IDO promotes tumor progression and predicts poor patient?s survival. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 25, 2014 Category: Cancer & Oncology Authors: Jing-Yi ChenChien-Feng LiCheng-Chin KuoKelvin TsaiMing-Feng HouWen-Chun Hung Source Type: research
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2 positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone
Conclusion:
PTEN was neither a significant prognostic nor predictive factor. PIK3CA mutations were an adverse prognostic factor for survival but not predictive for lapatinib benefit.Trial registrationClinicalTrials.gov NCT00281658 (registered 23 January 2006) (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 24, 2014 Category: Cancer & Oncology Authors: Binghe XuZhongzhen GuanZhenzhou ShenZhongshen TongZefei JiangJunlan YangMichelle DeSilvioMark RussoMeggan LeighCatherine Ellis Source Type: research
Nestin positively regulates the Wnt/ß-catenin pathway and the proliferation, survival, and invasiveness of breast cancer stem cells
IntroductionWe investigated Nestin expression in triple-negative breast cancer and examined how the modulation of Nestin expression affects cell cycle progression, survival, invasion and regulatory signaling in breast cancer stem cells (CSC) in vitro.
Methods:
Nestin expression in 150 triple-negative breast cancer specimens were examined by immunohistochemistry. The role of Nestin expression in tumorigenesis was examined by assaying naturally occurring Nestinhigh/Nestinlow CSC from 12 breast cancer tissues, as well as CSC from 26 clinical specimens, where Nestin overexpression and silencing was achieved by genetic manipula...
Source: Breast Cancer Research - July 24, 2014 Category: Cancer & Oncology Authors: Zuowei ZhaoPing LuHao ZhangHuanming XuNingning GaoMan LiCaigang Liu Source Type: research
The influence of tamoxifen on normal mouse mammary gland homeostasis
Conclusion:
Tamoxifen can skew the distribution of mammary cell types in a dose dependent manner, and thus caution must be taken when interpreting lineage tracing studies using high doses of tamoxifen, particular when short duration analyses of a quantitative nature are being performed. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 24, 2014 Category: Cancer & Oncology Authors: Mona ShehataRenée van AmerongenAmber ZeemanRajshekhar GiraddiJohn Stingl Source Type: research
Tumor homologous recombination deficiency assays: another step closer to clinical application?
Inherited and acquired defects in homologous recombination, a phenotype termed ‘BRCAness’, may lend to therapeutic exploitation in breast cancer. To this end, development and clinical evaluation of platforms to identify signatures of BRCAness are of immense interest. In this issue of Breast Cancer Research, Vollebergh and colleagues report that a BRCA-like array comparative genomic hybridization (aCGH) genomic instability signature is associated with benefit from high-dose cyclophosphamide-thiotepa-carboplatin chemotherapy. We discuss the strengths and weaknesses of this study and consider the clinical significance and...
Source: Breast Cancer Research - July 14, 2014 Category: Cancer & Oncology Authors: Shane SteckleinPriyanka Sharma Source Type: research
Ubiquitin-conjugating enzyme complex Uev1A-Ubc13 promotes breast cancer metastasis through nuclear factor-[cyrillic small letter ka]B mediated matrix metalloproteinase-1 gene regulation
Conclusions:
These results identify UEV1A as a potential therapeutic target in the treatment of metastasic breast cancers. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 14, 2014 Category: Cancer & Oncology Authors: Zhaojia WuSiqi ShenZhiling ZhangWeiwei ZhangWei Xiao Source Type: research
Peroxiredoxin-1 protects estrogen receptor alpha from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer
Conclusions:
PRDX1 is shown to be an independent predictor of improved outcomes in ER-positive breast cancer. Through its antioxidant function, PRDX1 may prevent oxidative stress-mediated ERalpha loss, thereby potentially contributing to maintenance of an ER-positive phenotype in mammary tumors. These results for the first time imply a close connection between biological activity of PRDX1 and regulation of estrogen-mediated signaling in breast cancer. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 10, 2014 Category: Cancer & Oncology Authors: Patrick O¿LearyMarta TerrileMalgorzata BajorPawel GajBryan HennessyGordon MillsAgnieszka ZagozdzonDarran O¿ConnorDonal BrennanKate ConnorJane LiAna Gonzalez-AnguloHan-Dong SunJian-Xin PuFredrik PonténMathias UhlénKarin JirströmDominika NowisJohn Crow Source Type: research
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study
Conclusions:
According to these analyses, and in line with other analyses of pertuzumab and trastuzumab in the neoadjuvant setting, we conclude that HER2 expression remains the only marker suitable for patient selection for this regimen at present.Trial registration: The TRYPHAENA study was registered with ClinicalTrials.gov, NCT00976989, on September 14 2009. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 8, 2014 Category: Cancer & Oncology Authors: Andreas SchneeweissStephen ChiaRoberto HeggChristoph TauschRahul DebJayantha RatnayakeVirginia McNallyGraham RossAstrid KiermaierJavier Cortés Source Type: research
Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status
Conclusions:
Our data corroborates epidemiologic data, suggesting that the etiology and pathogenesis of breast cancers vary by ER status, which may have implications for developing prevention strategies for these tumors. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 8, 2014 Category: Cancer & Oncology Authors: Melissa RotunnoXuezheng SunJonine FigueroaMark ShermanMontserrat Garcia-ClosasPaul MeltzerTyisha WilliamsSallie SchneiderD JerryXiaohong YangMelissa Troester Source Type: research
Developing a new generation of breast cancer clinical gene expression tests
When treatment decisions are based purely on clinicopathological factors, many women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative cancers are overtreated. Gene expression profiles are valuable clinical tools that stratify the recurrence risk to identify patients most likely to benefit from adjuvant systemic therapies. Building upon greater understanding of tumor biology and more rigorous approaches to validation (including independent studies with a high level of evidence), several second-generation multigene tests have been developed. In the previous issue, Martin and colleagues report...
Source: Breast Cancer Research - July 7, 2014 Category: Cancer & Oncology Authors: Zuzana KosTorsten Nielsen Source Type: research
Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification using an independent prospective breast cancer cohort and external patient populations
Conclusions:
Both prospective internal cohorts and the independent external cohorts reproduced the triad classification of CMTC and its prognostic significance. CMTC is an independent prognostic predictor, and it outperformed 12 other known prognostic gene signatures, molecular subtype classifications, and all other standard prognostic clinicopathological factors. Our results support further development of CMTC portfolio into a guide for personalized breast cancer treatments. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 4, 2014 Category: Cancer & Oncology Authors: Dong-Yu WangSusan DoneDavid Mc CreadyWey Leong Source Type: research
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients
Conclusions:
PPV could be feasible for mrTNBC patients because of the safety, immune responses, and possible clinical benefits.Clinical Trial Registration Number: UMIN000001844 (Registration Date: April 5, 2009) (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 3, 2014 Category: Cancer & Oncology Authors: Ryuji TakahashiUhi TohNobutaka IwakumaMiki TakenakaHiroko OtsukaMina FurukawaTeruhiko FujiiNaoko SekiAkihiko KawaharaMasayoshi KageSatoko MatsuedaYoshito AkagiAkira YamadaKyogo ItohTetsuro Sasada Source Type: research
